PROV
PROV
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
7 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
PROV has an insider buy conviction of 50%, compared to the Unknown sector buy average of 20%.
Multiple Insiders
S - Sale Insiders
$0 total
Over the last 90 days, corporate insiders at PROV (PROV) engaged in a total of 7 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for PROV shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (S - Sale Insiders), who traded 22.2K shares valued at $0 on Jun 10, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering PROV and the Unknown sector.
Tracking Insider Activity in Biotech: High Stakes and Hidden Signals
Biotech insiders possess unique asymmetric information, clinical results, FDA feedback, partnership negotiations. This guide explains how to track Form 4 activity at pre-commercial biotechs, what position sizes matter, and how to avoid false signals near data events.
Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree
2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.
Biotech Insider Buying: Analyzing Clinical Trial Catalysts
Biotech insiders walk a legal tightrope near trial readouts. This report identifies statistically significant buying clusters at small-cap biotechs 30-90 days before Phase 2 and Phase 3 data announcements.
Rule 10b5-1 Trading Plans: What Every Investor Must Know
Rule 10b5-1 plans allow corporate insiders to pre-schedule stock sales months in advance, providing them with an affirmative defense against insider trading allegations. This guide explains how these plans work, why they matter for interpreting insider transaction data, and the significant regulatory changes made by the SEC in 2023.
Why Biotech Insiders Purchase Prior to Phase 3 Results
Buying stock before Phase 3 results is the highest-risk insider trade in biotech. This report examines the legal boundaries, the statistical frequency of such purchases, and whether insiders who buy pre-Phase-3 have historically outperformed those who buy after.
The Role of Proxy Statements in Verifying C-Suite Stock Ownership
Proxy statements (DEF 14A) provide the definitive record of executive stock ownership, option grants, and compensation structure. This guide shows how to cross-reference proxy data with Form 4 filings to verify insider conviction claims.
FAQs About PROV Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for PROV.